HRP20130127T1 - Prediktivni biomarkeri bubrežne sigurnosti i potpisi biomarkera za praä†enje funkcije bubrega - Google Patents

Prediktivni biomarkeri bubrežne sigurnosti i potpisi biomarkera za praä†enje funkcije bubrega Download PDF

Info

Publication number
HRP20130127T1
HRP20130127T1 HRP20130127AT HRP20130127T HRP20130127T1 HR P20130127 T1 HRP20130127 T1 HR P20130127T1 HR P20130127A T HRP20130127A T HR P20130127AT HR P20130127 T HRP20130127 T HR P20130127T HR P20130127 T1 HRP20130127 T1 HR P20130127T1
Authority
HR
Croatia
Prior art keywords
substance
administration
microglobulin
biomarkers
sample
Prior art date
Application number
HRP20130127AT
Other languages
English (en)
Inventor
Gerard Maurer
Frank Dieterle
Elias Perentes
Frank STÄDTLER
André Cordier
Andreas Mahl
Jacky Vonderscher
Daniel Wahl
Olivier Grenet
Daniel Robert Roth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20130127T1 publication Critical patent/HRP20130127T1/hr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (3)

1. Postupak za procjenu bubrežne toksičnosti kod pojedinca nakon davanja spoja za koji se sumnja da izaziva bubrežnu toksičnost, naznačen time da se bubrežna toksičnost utvrđuje mjerenjem skupa biomarkera u uzorku urina pojedinca, te se provodi usporedba iznosa izmjerenih biomarkera s odgovarajućim iznosom kod zdravog pojedinca, pri čemu su biomarkeri su odabrani iz skupine koja se sastoji od biomarkera navedenih u tablici 1, a uključuju 2-mikroglobulinski protein, te gdje renalna toksičnost su glomerulske promjene ili oštećenja.
2. Postupak za dijagnosticiranje, predviđanje i klasifikaciju bubrežne toksičnosti naznačen time da se koristi β-2-mikroglobulinski protein u urinu za prikazivanje glomerulskih promjena ili oštećenja.
3. Postupak za praćenje učinkovitosti liječenja subjekta s nekom tvari naznačen time da obuhvaća sljedeće korake: (i) dobivanje uzorka urina od subjekta prije davanja tvari, (ii) otkrivanje razine ekspresije β-2-mikroglobulina u uzorku prije davanja tvari, (iii) dobivanje jednog ili više uzoraka urina od subjekta nakon davanja tvari, (iv) otkrivanje razine ekspresije β-2-mikroglobulina u uzorku poslije davanja tvari, (v) uspoređivanje razine ekspresije β-2-mikroglobulina u uzorku prije davanja tvari s razinom ekspresije β-2-mikroglobulina u uzorku ili uzorcima poslije davanja tvari, te (vi) odgovarajuće promjene davanja tvari subjektu.
HRP20130127AT 2007-03-26 2013-02-13 Prediktivni biomarkeri bubrežne sigurnosti i potpisi biomarkera za praä†enje funkcije bubrega HRP20130127T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90809407P 2007-03-26 2007-03-26
PCT/EP2008/053504 WO2008116867A1 (en) 2007-03-26 2008-03-25 Predictive renal safety biomarkers and biomarker signatures to monitor kidney function

Publications (1)

Publication Number Publication Date
HRP20130127T1 true HRP20130127T1 (hr) 2013-03-31

Family

ID=39325830

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130127AT HRP20130127T1 (hr) 2007-03-26 2013-02-13 Prediktivni biomarkeri bubrežne sigurnosti i potpisi biomarkera za praä†enje funkcije bubrega

Country Status (15)

Country Link
US (2) US8609812B2 (hr)
EP (12) EP2479574A3 (hr)
JP (2) JP5450375B2 (hr)
CN (2) CN101679525B (hr)
AU (1) AU2008231738B2 (hr)
BR (1) BRPI0809432A2 (hr)
CA (1) CA2681792A1 (hr)
DK (1) DK2125899T3 (hr)
ES (4) ES2532220T3 (hr)
HR (1) HRP20130127T1 (hr)
PL (1) PL2125899T3 (hr)
PT (1) PT2125899E (hr)
RU (1) RU2519148C2 (hr)
SI (1) SI2125899T1 (hr)
WO (1) WO2008116867A1 (hr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5946990B2 (ja) 2007-08-29 2016-07-06 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 化粧品及び医薬品使用のための精油を含有する糖系界面活性剤マイクロエマルジョン
US11150250B2 (en) 2008-08-28 2021-10-19 Astute Medical, Inc. Methods for diagnosing acute kidney injury or renal failure
EP2813848A3 (en) 2008-08-29 2015-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103760359B (zh) * 2008-10-21 2017-01-11 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ619918A (en) * 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BRPI0922021A2 (pt) 2008-11-10 2019-09-24 Astute Medical Inc método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
US20110229915A1 (en) * 2008-11-22 2011-09-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8465980B2 (en) 2009-01-28 2013-06-18 Industrial Technology Research Institute Urine and serum biomarkers associated with diabetic nephropathy
WO2011017654A1 (en) 2009-08-07 2011-02-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5567600B2 (ja) * 2009-02-06 2014-08-06 メタボロン インコーポレイテッド 薬剤の肝毒性の判定
NZ601575A (en) * 2009-02-06 2014-08-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and failure
EP2425257A1 (en) * 2009-04-30 2012-03-07 Roche Diagnostics GmbH Means and methods for the differentiation of cardiac and diabetes mellitus-based causes of kidney damage
CA2766228A1 (en) * 2009-07-02 2011-01-06 Mosaiques Diagnostics And Therapeutics Ag Process and markers for the diagnosis of acute renal failure
EP2462437A4 (en) * 2009-08-07 2013-01-30 Rules Based Medicine Inc METHOD AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISEASES THEREOF
CN102725635B (zh) 2009-11-07 2015-05-20 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US8716453B2 (en) 2009-12-17 2014-05-06 School Juridical Person Kitasato Institute Cystatin C, β2 microglobulin, α1 microglobulin and genes for same, antibody, and kit and method for diagnosis of feline nephropathy
ES2818138T3 (es) 2009-12-20 2021-04-09 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
KR101940014B1 (ko) 2010-02-05 2019-01-21 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
AU2011220413B2 (en) 2010-02-26 2015-07-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
JP5855094B2 (ja) 2010-06-03 2016-02-09 アイデックス ラボラトリーズ インコーポレイテッドＩＤＥＸＸ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． 腎疾患のためのマーカー
AU2011269775B2 (en) 2010-06-23 2015-01-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ703055A (en) 2010-06-23 2016-07-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5830329B2 (ja) * 2010-09-28 2015-12-09 国立大学法人 岡山大学 腎障害の新規マーカー
JP2013539861A (ja) * 2010-10-07 2013-10-28 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN102147413A (zh) * 2010-12-08 2011-08-10 武汉生之源生物科技有限公司 一种小粒径匀相溶胶颗粒型胱抑素c测定试剂盒及其制备方法
CN102353782A (zh) * 2010-12-31 2012-02-15 上海华谷生物技术有限公司 抗人肾损伤分子1的体外诊断试剂盒及检测方法
CN102243241A (zh) * 2011-04-07 2011-11-16 武汉生之源生物科技有限公司 一种匀相溶胶颗粒型中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒及其制备方法
US20140171522A1 (en) * 2011-07-09 2014-06-19 Astute Medical, Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PT2748605T (pt) * 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
US20130062516A1 (en) * 2011-09-09 2013-03-14 Hsien-Shou Kuo Diganosis of a renal disease by oxygen and hydrogen isotopes in a biological sample
WO2013067420A1 (en) * 2011-11-03 2013-05-10 Tumlin James A Acth for treatment of kidney disease
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
GB201210587D0 (en) * 2012-06-14 2012-08-01 Belfast Health And Social Care Trust Predictive biomarker
US20150177260A1 (en) * 2012-07-23 2015-06-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of sepsis
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
ES2926197T3 (es) 2013-01-17 2022-10-24 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
CN104280477B (zh) * 2014-11-03 2016-03-30 天津中医药大学 内源性小分子物质在快速检测肝毒性方面的应用
US11037070B2 (en) * 2015-04-29 2021-06-15 Siemens Healthcare Gmbh Diagnostic test planning using machine learning techniques
CN108271422A (zh) 2015-06-25 2018-07-10 株式会社国际电气通信基础技术研究所 基于器官间串扰系统的预测装置及预测程序
JP6733968B2 (ja) * 2015-08-31 2020-08-05 日立化成株式会社 腎移植後合併症を評価するための分子法
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
US11180539B2 (en) 2016-03-29 2021-11-23 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
US20190218587A1 (en) * 2016-03-29 2019-07-18 Advanced Telecommunications Research Institute International Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure
CA3026502A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US11479818B2 (en) 2016-06-17 2022-10-25 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
CN106126972B (zh) * 2016-06-21 2018-10-02 哈尔滨工业大学 一种用于蛋白质功能预测的层级多标签分类方法
EP3568695A4 (en) 2017-01-12 2020-12-16 Astute Medical, Inc. METHODS AND COMPOSITIONS FOR THE EVALUATION AND TREATMENT OF KIDNEY INJURY AND RENAL FAILURE BASED ON A MEASUREMENT OF LIGAND CHEMIOKINE ON C-C 14
EP3577458A4 (en) 2017-02-06 2021-04-07 Astute Medical, Inc. METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF RENAL LESION AND RENAL INSUFFICIENCY
RU2687256C1 (ru) * 2018-03-26 2019-05-08 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ персонализированного лечения хронической болезни почек у больных с диабетической нефропатией
CN111647670A (zh) * 2019-03-04 2020-09-11 中国医学科学院药物研究所 一种与肾病综合征相关的肠道菌属Faecalitalea及其应用
RU2761730C1 (ru) * 2020-12-25 2021-12-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ дифференциальной диагностики уремического панкреатита и деструктивного панкреатита у пациентов, получающих заместительную почечную терапию - программный гемодиализ
RU2761732C1 (ru) * 2020-12-26 2021-12-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ дифференциальной диагностики уремического псевдоперитонита и перитонита у пациентов, получающих заместительную почечную терапию - программный гемодиализ
RU2761725C1 (ru) * 2020-12-26 2021-12-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ дифференциальной диагностики уремического псевдоперитонита и перитонита у пациентов, получающих заместительную почечную терапию - программный гемодиализ
RU2761733C1 (ru) * 2020-12-28 2021-12-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ дифференциальной диагностики уремического панкреатита и деструктивного панкреатита у пациентов, получающих заместительную почечную терапию - программный гемодиализ
CN115469026B (zh) * 2022-07-14 2023-10-20 中日友好医院(中日友好临床医学研究所) 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013877A1 (en) * 1995-10-12 1997-04-17 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
WO1999015904A1 (en) 1997-09-26 1999-04-01 University Of Washington Methods and compositions for diagnosing renal pathologies
ATE398286T1 (de) 1999-10-13 2008-07-15 Fuso Pharmaceutical Ind Verfahren zur diagnose von hämolytisch-uremischem syndrom und intestinalen hämorrhagischen infektionen durch escherichia coli& xa;
RU2180965C1 (ru) 2000-07-03 2002-03-27 Габбасова Наталья Вадимовна Способ дифференциальной диагностики заболеваний почек
AU2001281322A1 (en) 2000-07-13 2002-01-30 Biogen, Inc. Methods of identifying renal protective factors
ATE433571T1 (de) * 2001-10-02 2009-06-15 Ikagaku Co Ltd Methode zur diagnose von nierenerkrankungen
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
CN102183656B (zh) * 2003-03-27 2014-04-16 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
JP2006526405A (ja) * 2003-06-04 2006-11-24 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 示差的調節された肝細胞癌遺伝子およびその利用
UA88879C2 (en) * 2003-09-02 2009-12-10 Эплайд Рисерч Системз Эрс Холдинг Н.В. Fsh glycosylation mutant
CA2562343A1 (en) * 2004-04-07 2005-10-27 Gene Logic, Inc. Hepatotoxicity molecular models
WO2006056037A1 (en) 2004-09-21 2006-06-01 University Of Manitoba Method of detecting kidney dysfunction
GB0507838D0 (en) * 2005-04-18 2005-05-25 Epsom & St Helier University H A method of measuring the glomerular filtration rate of an human or animal patient, a self-use kit for providing blood samples for use in measuring glomerular
AU2006342958A1 (en) * 2005-12-22 2007-11-08 Bellus Health (International) Limited Treatment of renal disorders, diabetic nephropathy and dyslipidemias
US7867719B2 (en) * 2006-03-11 2011-01-11 Vermillion, Inc. Beta-2 microglobulin as a biomarker for peripheral artery disease
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
WO2008057806A1 (en) * 2006-11-01 2008-05-15 Vermillion, Inc. A panel of biomarkers for peripheral arterial disease

Also Published As

Publication number Publication date
PT2125899E (pt) 2013-01-24
EP2479574A2 (en) 2012-07-25
SI2125899T1 (sl) 2013-02-28
EP2479572B1 (en) 2014-12-24
EP2479573A2 (en) 2012-07-25
EP2479569A2 (en) 2012-07-25
EP2479564A3 (en) 2012-09-26
DK2125899T3 (da) 2013-02-11
AU2008231738A1 (en) 2008-10-02
AU2008231738B2 (en) 2012-09-27
ES2532221T3 (es) 2015-03-25
EP2479566A3 (en) 2012-09-26
EP2479571A2 (en) 2012-07-25
WO2008116867A1 (en) 2008-10-02
JP2014074721A (ja) 2014-04-24
EP2479564A2 (en) 2012-07-25
EP2479571A3 (en) 2012-09-26
EP2479568B1 (en) 2015-01-07
EP2479574A3 (en) 2012-09-26
EP2479565A3 (en) 2012-09-26
EP2479569A3 (en) 2012-09-26
JP5450375B2 (ja) 2014-03-26
RU2009139295A (ru) 2011-05-10
ES2532220T3 (es) 2015-03-25
RU2519148C2 (ru) 2014-06-10
EP2479567A3 (en) 2012-09-26
CN101679525A (zh) 2010-03-24
EP2479568A2 (en) 2012-07-25
ES2397484T3 (es) 2013-03-07
JP2010522871A (ja) 2010-07-08
CN103399155A (zh) 2013-11-20
EP2479568A3 (en) 2012-09-26
US8609812B2 (en) 2013-12-17
EP2479572A2 (en) 2012-07-25
EP2479566A2 (en) 2012-07-25
EP2479565A2 (en) 2012-07-25
CN101679525B (zh) 2013-06-19
EP2479567A2 (en) 2012-07-25
EP2125899A1 (en) 2009-12-02
PL2125899T3 (pl) 2013-04-30
ES2532229T3 (es) 2015-03-25
EP2125899B1 (en) 2012-11-14
CA2681792A1 (en) 2008-10-02
EP2479566B1 (en) 2015-01-07
US20100143956A1 (en) 2010-06-10
US20140171335A1 (en) 2014-06-19
BRPI0809432A2 (pt) 2014-09-09
EP2479570A3 (en) 2012-09-26
EP2479572A3 (en) 2012-09-26
EP2479573A3 (en) 2012-09-26
EP2479570A2 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
HRP20130127T1 (hr) Prediktivni biomarkeri bubrežne sigurnosti i potpisi biomarkera za praä†enje funkcije bubrega
Urbschat et al. Biomarkers of kidney injury
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
JP2009501333A5 (hr)
BR112012019542A2 (pt) "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit"
WO2011079938A3 (en) System and method for determining the concentration of an analyte in a sample fluid
NZ619918A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010057184A3 (en) Methods for detection of acute kidney injury in humans
RU2008103988A (ru) Способ диагностики рассеяного склероза
WO2009101059A3 (en) Methods of using cadherin 11 (cdh11) antagonists
EP3156925A3 (en) Copd biomarker signatures
NZ624609A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Yilmaz et al. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease
NZ624614A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2012007009A (es) Método para diagnosticar un tumor maligno.
WO2009001545A1 (ja) 移植片対宿主疾患の検査および治療方法
Petritz et al. Evaluation of portable blood glucose meters for measurement of blood glucose concentration in ferrets (Mustela putorius furo)
BRPI0709271B8 (pt) métodos para a detecção de uma doença renal
WO2008132464A3 (en) Mek5 and related proteins as biomarkers of neurodegenerative diseases
EA201290056A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
NZ628085A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
JP2008504551A5 (hr)
Gao et al. Urinary AQP5 is independently associated with eGFR decline in patients with type 2 diabetes and nephropathy